Oh Minyoung, Brumberg Joachim, Sossi Vesna, Varrone Andrea
Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden;
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
J Nucl Med. 2025 Feb 3;66(2):309-314. doi: 10.2967/jnumed.124.268233.
Serotonin transporter (SERT) availability was assessed using 2 tracers, [C],-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine ([C]DASB) and [C],-dimethyl-2-(2-amino-4-fluoromethylphenylthio)benzylamine) ([C]MADAM), in independent cohorts of patients and controls. This study aimed to independently confirm whether SERT remains intact in nondepressed individuals with early-stage Parkinson disease (PD), because the use of diverse methodologies could potentially yield disparate results. Seventeen PD patients (5 women and 12 men; age, 64 ± 7 y; Unified Parkinson's Disease Rating Scale motor score, 23 ± 5; Beck Depression Inventory score, 5 ± 4) and 20 age- and sex-matched healthy controls underwent [C]MADAM PET at Karolinska Institutet. Fifteen PD patients (5 women and 10 men; age, 59 ± 9 y; Unified Parkinson's Disease Rating Scale motor score, 15 ± 7; Beck Depression Inventory score, 4 ± 4) and 8 controls were examined with [C]DASB PET at the University of British Columbia. PET scans were performed at both institutions using a high-resolution research tomograph. A simplified reference tissue model and Logan graphical analysis were used to calculate the regional nondisplaceable binding potential (BP), using the cerebellum as the reference. Parametric BP images were generated using wavelet-aided parametric imaging. MRI-defined volumes of interest included cortical and subcortical regions, as well as brain stem nuclei. There were no significant differences between controls and early-stage PD patients in either the [C]DASB or the [C]MADAM cohort, regardless of the analysis method. Group differences (Cohen ) in the [C]DASB cohort ranged from 0.34 to 0.86 in brain stem nuclei, 0.09 to 0.61 in subcortical regions, and 0.28 to 0.70 in cortical regions. In the [C]MADAM cohort, they ranged from 0.16 to 0.40, 0.19 to 0.55, and 0.32 to 0.61, respectively. Logan BP highly correlated with simplified reference tissue model BP for both tracers in each group ( < 0.001). SERT availability is relatively preserved in nondepressed patients with PD. This study suggests that serotonergic degeneration is not a major feature of the disease in nondepressed patients with nonadvanced disease.
使用两种示踪剂[¹¹C] - 二甲基 - 2 - (2 - 氨基 - 4 - 氰基苯基硫代)苄胺([¹¹C]DASB)和[¹¹C] - 二甲基 - 2 - (2 - 氨基 - 4 - 氟甲基苯基硫代)苄胺([¹¹C]MADAM)，在独立的患者和对照队列中评估血清素转运体(SERT)的可用性。本研究旨在独立确认早期帕金森病(PD)的非抑郁个体中SERT是否保持完整，因为使用不同的方法可能会产生不同的结果。17名PD患者(5名女性和12名男性；年龄，64±7岁；统一帕金森病评定量表运动评分，23±5；贝克抑郁量表评分，5±4)和20名年龄和性别匹配的健康对照在卡罗林斯卡学院接受了[¹¹C]MADAM正电子发射断层扫描(PET)。15名PD患者(5名女性和10名男性；年龄，59±9岁；统一帕金森病评定量表运动评分，15±7；贝克抑郁量表评分，4±4)和8名对照在英属哥伦比亚大学接受了[¹¹C]DASB PET检查。两个机构均使用高分辨率研究断层扫描仪进行PET扫描。使用简化参考组织模型和洛根图形分析法，以小脑作为参考，计算区域不可置换结合潜力(BP)。使用小波辅助参数成像生成参数BP图像。MRI定义的感兴趣区域包括皮质和皮质下区域以及脑干核。在[¹¹C]DASB或[¹¹C]MADAM队列中，无论分析方法如何，对照组和早期PD患者之间均无显著差异。[¹¹C]DASB队列中的组间差异(科恩d值)在脑干核中为0.34至0.86，在皮质下区域为0.09至0.61，在皮质区域为0.28至0.70。在[¹¹C]MADAM队列中，它们分别为0.16至0.40、0.19至0.55和0.32至0.61。每组中两种示踪剂的洛根BP与简化参考组织模型BP高度相关(P<0.001)。PD非抑郁患者的SERT可用性相对保留。本研究表明，在疾病未进展的非抑郁PD患者中，血清素能变性不是该疾病的主要特征。
